Study to understand why lymphoma treatments stop working
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks for why some lymphomas do not respond to treatment. By studying your blood cells, doctors hope to find new ways to help patients fight this cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer called B-cell non-Hodgkin lymphoma (B-NHL), either when first diagnosed or if it has come back.
- You are 18 years old or older.
- You are covered by a social security system (like health insurance or national health coverage).
- You are not under legal guardianship or protective custody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “cell-free DNA,” meaning tiny bits of DNA found in blood, in people with mature B-cell lymphoma. It may help doctors understand the disease better and how blood tests could be used to monitor it.
This study looks at certain markers on your blood cancer cells to understand them better. By joining, you help doctors learn more about your disease, which may guide future care.
This study looks at real-world data from people with non-Hodgkin lymphoma that involves organs or tissues beyond the lymph nodes. It aims to understand how well different treatments work, so your experience can help improve future care.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study looks at blood (“hematopoietic”) information in people age 60+ with relapsed B-cell non-Hodgkin lymphoma who need an additional round of treatment. It may help researchers understand changes in the body during active lymphoma therapy.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
Hear when a new MATURE B-CELL LYMPHOIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.